FDA Drug Safety Meetings Begin In May
This article was originally published in The Pink Sheet Daily
Executive Summary
Advantages and disadvantages of current safety signal detection system to be discussed at May 18-19 meeting of FDA's Drug Safety & Risk Management Advisory Committee. Meeting is first in a series on drug safety issues, FDA says.
You may also be interested in...
Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options
Pfizer is characterizing FDA's request for a withdrawal of Bextra as a "marketing suspension"; the company hopes to continue discussions on how valdecoxib could re-enter the market. Increased cardiovascular risk plus a "special risk" of serious skin reactions led FDA to recommend pulling the COX-2 inhibitor.
Independent Drug Safety Oversight Could Lead To Over-Reactions - Enzi
Legislation establishing an independent drug safety oversight group for FDA could result in over-reactions to drug safety signals, Senate Health Committee Chairman Michael Enzi (R-Wyo.) told the Food & Drug Law Institute annual conference April 7 in Washington, D.C
FDA Science Board To Discuss Pre- And Postmarketing Safety
The scientific advisory panel will discuss the agency's pre- and postmarketing safety programs for drugs and biologics at an April 15 meeting. The group will also discuss good manufacturing practices for vaccines; blood; and cell, tissue and gene products.